At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 475 enrolled
Drug / intervention
Convalescent Plasma +1 morebiological
Likely dose
Convalescent Plasma 2 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial
In Brief
A Phase 2 clinical trial evaluating Convalescent Plasma and Standard of Care for Covid19 and 4 related conditions. Completed, enrolled 475 participants across 17 sites.
Detailed Summary
The principal objective of the CONFIDENT trial is to assess the efficacy of two units (400-500 mL in total) of convalescent plasma, as compared to Standard of Care (SoC), to reduce day-28 mortality in patients with SARS-CoV-2 pneumonia who require mechanical ventilation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Mechanical Ventilation Complication, Corona Virus Infection, Respiratory Failure, SARS (Severe Acute Respiratory Syndrome)
CountriesBelgium
CollaboratorsKCE Belgian Healthcare Knowledge Centre
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedSep 2020
Primary CompletionApr 2022
Study CompletionMar 2023
TodayJul 2026
First PostedSep 22, 2020
Enrollment StartSep 11, 2020
Primary CompletionApr 9, 2022
Study CompletionMar 9, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.8 years ago
Interventions
Convalescent Plasmabiological
2 units of convalescent plasma
Standard of Careother
Gold Standards